.jpg)
Lithuania: Emerging Life Science Leader
Lithuania is an EU member state boasting the largest economy among its neighboring Baltic states.
According to Labiotech1, Lithuania’s life science sector is growing at an approximate rate of 20-25% per year, with 90% of the country’s life science products and services being exported internationally.
Lithuania’s prestigious and state-subsidized university system fosters a highly educated workforce and promotes collaboration between academia and industry to advance scientific research and drive innovation.
Reference:
1. Bancroft D. What Is Lithuania's Role in European Biotech? Labiotech.eu Web site. https://labiotech.eu/policy-legal-finance/biotech-lithuania/. Accessed May 22,2019.
Flexible, Modern Facilities
Northway Biotech operates two state-of-the-art facilities in Vilnius, Lithuania, designed to support the development and manufacturing of protein-based biologics and gene therapies.
Our biologics facility includes more than 40 advanced R&D laboratories for cell line development, upstream/downstream process development, and analytical services, alongside cGMP manufacturing suites equipped with both single-use and stainless steel systems. This site supports microbial and mammalian expression platforms and offers full drug substance production as well as aseptic fill-finish capabilities.
In 2024, we expanded our footprint with the opening of the Baltics’ first dedicated gene therapy manufacturing center - an 8,000 m² facility purpose-built for cGMP production of viral vectors and plasmid DNA. This site delivers end-to-end gene therapy CDMO services, including vector production, cell banking, and viral clearance studies.
Together, these two facilities form a robust, flexible, and scalable infrastructure for clients seeking high-quality, integrated biologics and gene therapy manufacturing solutions in the heart of Europe.
